1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C - Drugs In Development, 2022, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hepatitis C - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 10, 8, 14, 30, 22 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 13 and 17 molecules, respectively.
Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Hepatitis C - Overview
- Hepatitis C - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hepatitis C - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hepatitis C - Companies Involved in Therapeutics Development
- Hepatitis C - Drug Profiles
- Hepatitis C - Dormant Projects
- Hepatitis C - Discontinued Products
- Hepatitis C - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Hepatitis C, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Hepatitis C - Pipeline by AB Pharma Ltd, 2022
- Hepatitis C - Pipeline by AbbVie Inc, 2022
- Hepatitis C - Pipeline by Acceleromics SL, 2022
- Hepatitis C - Pipeline by Apexian Pharmaceuticals Inc, 2022
- Hepatitis C - Pipeline by Ascletis Pharma Inc, 2022
- Hepatitis C - Pipeline by Atea Pharmaceuticals Inc, 2022
- Hepatitis C - Pipeline by Auro Vaccines LLC, 2022
- Hepatitis C - Pipeline by Beta Pharma Inc, 2022
- Hepatitis C - Pipeline by Biotron Ltd, 2022
- Hepatitis C - Pipeline by Bolder Biotechnology Inc, 2022
- Hepatitis C - Pipeline by Bugworks Research India Pvt Ltd, 2022
- Hepatitis C - Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
- Hepatitis C - Pipeline by Cocrystal Pharma Inc, 2022
- Hepatitis C - Pipeline by ConserV Bioscience Ltd, 2022
- Hepatitis C - Pipeline by DEKK-TEC Inc, 2022
- Hepatitis C - Pipeline by Dongguan HEC TaiGen Biopharmaceuticals Co Ltd, 2022
- Hepatitis C - Pipeline by Eagle Pharmaceuticals Inc, 2022
- Hepatitis C - Pipeline by Ena Therapeutics Pty Ltd, 2022
- Hepatitis C - Pipeline by Ennaid Therapeutics LLC, 2022
- Hepatitis C - Pipeline by Escient Pharmaceuticals Inc, 2022
- Hepatitis C - Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Hepatitis C - Pipeline by FortuneRock (China) Ltd, 2022
- Hepatitis C - Pipeline by Galactica Biotech Ltd, 2022
- Hepatitis C - Pipeline by GeneCure Biotechnologies LLC, 2022
- Hepatitis C - Pipeline by GeneOne Life Science Inc, 2022
- Hepatitis C - Pipeline by Genoscience Pharma, 2022
- Hepatitis C - Pipeline by Gilead Sciences Inc, 2022
- Hepatitis C - Pipeline by GSK plc, 2022
- Hepatitis C - Pipeline by HEC Pharma Co Ltd, 2022
- Hepatitis C - Pipeline by Hepion Pharmaceuticals Inc, 2022
- Hepatitis C - Pipeline by ImmunoBiology Ltd, 2022
- Hepatitis C - Pipeline by Inovio Pharmaceuticals Inc, 2022
- Hepatitis C - Pipeline by Integrated BioTherapeutics Inc, 2022
- Hepatitis C - Pipeline by iQur Ltd, 2022
- Hepatitis C - Pipeline by J2H Biotech, 2022
- Hepatitis C - Pipeline by Maxwell Biosciences Inc, 2022
- Hepatitis C - Pipeline by Medivir AB, 2022
- Hepatitis C - Pipeline by Merck & Co Inc, 2022
- Hepatitis C - Pipeline by MetalloPharm LLC, 2022
- Hepatitis C - Pipeline by Microbio Co Ltd, 2022
- Hepatitis C - Pipeline by Nanjing Sanhome Pharmaceutical Co Ltd, 2022
- Hepatitis C - Pipeline by Novalex Therapeutics Inc, 2022
- Hepatitis C - Pipeline by Ono Pharmaceutical Co Ltd, 2022
- Hepatitis C - Pipeline by Palisades Therapeutics, 2022
- Hepatitis C - Pipeline by PharmaEssentia Corp, 2022
- Hepatitis C - Pipeline by Presidio Pharmaceuticals Inc, 2022
- Hepatitis C - Pipeline by Regulus Therapeutics Inc, 2022
- Hepatitis C - Pipeline by Resilience Biotechnologies Inc, 2022
- Hepatitis C - Pipeline by Riboscience LLC, 2022
- Hepatitis C - Pipeline by Rodos BioTarget GmbH, 2022
- Hepatitis C - Pipeline by Savoy Pharmaceuticals Inc, 2022
- Hepatitis C - Pipeline by Shanghai Newsummit Biopharma Co Ltd, 2022
- Hepatitis C - Pipeline by Shanghai Tangrun Pharmaceuticals Co Ltd, 2022
- Hepatitis C - Pipeline by Shionogi & Co Ltd, 2022
- Hepatitis C - Pipeline by Sino Biopharmaceutical Ltd, 2022
- Hepatitis C - Pipeline by Statera Biopharma Inc, 2022
- Hepatitis C - Pipeline by Sudershan Biotech Ltd, 2022
- Hepatitis C - Pipeline by TaiGen Biotechnology Co Ltd, 2022
- Hepatitis C - Pipeline by Tetranov International Inc, 2022
- Hepatitis C - Pipeline by Toray Industries Inc, 2022
- Hepatitis C - Pipeline by UBI Pharma Inc, 2022
- Hepatitis C - Pipeline by Uvax Bio LLC, 2022
- Hepatitis C - Pipeline by Vanworld Pharmaceutical (Rugao) Company Ltd, 2022
- Hepatitis C - Pipeline by Vertex Pharmaceuticals Inc, 2022
- Hepatitis C - Pipeline by Virocovax, 2022
- Hepatitis C - Pipeline by Zylacta Corp, 2022
- Hepatitis C - Dormant Projects, 2022
- Hepatitis C - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Hepatitis C, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AB Pharma Ltd
- AbbVie Inc
- Acceleromics SL
- Apexian Pharmaceuticals Inc
- Ascletis Pharma Inc
- Atea Pharmaceuticals Inc
- Auro Vaccines LLC
- Beta Pharma Inc
- Biotron Ltd
- Bolder Biotechnology Inc
- Bugworks Research India Pvt Ltd
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Cocrystal Pharma Inc
- ConserV Bioscience Ltd
- DEKK-TEC Inc
- Dongguan HEC TaiGen Biopharmaceuticals Co Ltd
- Eagle Pharmaceuticals Inc
- Ena Therapeutics Pty Ltd
- Ennaid Therapeutics LLC
- Escient Pharmaceuticals Inc
- F. Hoffmann-La Roche Ltd
- FortuneRock (China) Ltd
- Galactica Biotech Ltd
- GeneCure Biotechnologies LLC
- GeneOne Life Science Inc
- Genoscience Pharma
- Gilead Sciences Inc
- GSK plc
- HEC Pharma Co Ltd
- Hepion Pharmaceuticals Inc
- ImmunoBiology Ltd
- Inovio Pharmaceuticals Inc
- Integrated BioTherapeutics Inc
- iQur Ltd
- J2H Biotech
- Maxwell Biosciences Inc
- Medivir AB
- Merck & Co Inc
- MetalloPharm LLC
- Microbio Co Ltd
- Nanjing Sanhome Pharmaceutical Co Ltd
- Novalex Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- Palisades Therapeutics
- PharmaEssentia Corp
- Presidio Pharmaceuticals Inc
- Regulus Therapeutics Inc
- Resilience Biotechnologies Inc
- Riboscience LLC
- Rodos BioTarget GmbH
- Savoy Pharmaceuticals Inc
- Shanghai Newsummit Biopharma Co Ltd
- Shanghai Tangrun Pharmaceuticals Co Ltd
- Shionogi & Co Ltd
- Sino Biopharmaceutical Ltd
- Statera Biopharma Inc
- Sudershan Biotech Ltd
- TaiGen Biotechnology Co Ltd
- Tetranov International Inc
- Toray Industries Inc
- UBI Pharma Inc
- Uvax Bio LLC
- Vanworld Pharmaceutical (Rugao) Company Ltd
- Vertex Pharmaceuticals Inc
- Virocovax
- Zylacta Corp
